EagleBio is pleased to share a list below of publications referencing use of our Shikari Kits from Matriks Biotek. Our Shikari Kits are esoteric assays and are not only the gold standard of anti-drug antibody kits world worldwide but are also incredibly user friendly.
Click the links below for further details.
Publications:
Adisen E, et al, Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study, Journal of Dermatology (2010)
Aydın C, Ataoğlu H., Demonstration of β-1,2 Mannan Structures Expressed on the Cell Wall of Candida albicans Yeast Form But Not on the Hyphal Form by Using Monoclonal Antibodies(2015).
Bodini G, et
al, Clinical relevance of Adalimumab serum concentration and Anti-Adalimumab
antibodies in patients with Chrohn’s disease during long-term follow up, Italy
(2012)
Bortlik M, et al, Impact of Anti-Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children
Bortlik
M, et al, Infliximab trough levels may predict sustained response to infliximab
in patients with Crohn’s disease, Journal of Crohn’s and Colitis (2012) Bortlik
M, et al, Infliximab trough levels may predict sustained response to infliximab
in patients with Crohn’s disease, Journal of Crohn’s and Colitis (2012)
Bortlik M et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study, by using Matriks Biotek®, SHIKARI® Q-INFLIXI and SHIKARI® Q-ADA (infliximab and adalimumab)) ELISA Kits IBD Clinical and Research Centre, ISCARE, Charles University , Prague , Czech Republic
Chio C, et al, Etanercept Attenuates Traumatic
Brain Injury in Rats by Reducing Brain TNF-α Contents and by Stimulating Newly
Formed Neurogenesis, Mediators of Inflammation, (2013)
Erdemli Ö., et al, In vitro evaluation of effects of sustained anti-TNF release from MPEG-PCL-MPEG and PCL microspheres on human rheumatoid arthritis synoviocytes.
Gabriela Romero, et al, Poly(Lactide-co-Glycolide) Nanoparticles, Layer by Layer Engineered for the Sustainable Delivery of AntiTNF-α.
Grosen A., et al, Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease (2013).
Gutierrez A, et al, Genetic susceptibility to increased
bacterial translocation influences the response to biological therapy in
patients with Crohn’s disease, Gut (2013)
Jung Y, et al, Temperature-modulated noncovalent interaction controllable complex for the long-term delivery of etanercept to treat rheumatoid arthritis, (2013).
Kato S, et al, Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient, Crohn’s & Colitis Foundation of America (2011)
Kato S, et al, Elevated Serum IgE Prior to Acute Severe Infusion Reaction During Infliximab Maintenance Therapy in a Crohn’s Disease Patient, Crohn’s & Colitis Foundation of America (2011)
Krajcovicova A. et al., Delayed hypersensitivity reaction after initial dose of infliximab: a case report (2014)
Malickova K, et al, Phosphatidylserine-dependent
anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with
inflammatory bowel diseases, Autoimmun Highlights (2012)
Molnar T, et al, Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease, Hungary (2012)
Pallagi-Kunstár Éva et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease (2014) Pallagi-Kunstár Éva et al., Utility of serum TNF-a, infliximab trough level, and antibody titers in inflammatory bowel disease (2014)
Takahashi H, et al, Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis, Journal of Dermatology (2012)
Seok Lee Y, et al, Efficacy of Early Infliximab Treatment for Pediatric Crohn’s Disease: A Three-year Follow-up, Pediatric Gastroenterology, Hepatology & Nutrition (2012)
Related News:
Matriks Introduces Eagle Biosciences, Inc. As Distributor in North America
New Publication Presented at UEG For Therapeutic Drug Monitoring Using EagleBio’s SHIKARI® ELISA Kits from Matriks
Related Kits:
Shikari ELISA Assay Kits
